<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921310</url>
  </required_header>
  <id_info>
    <org_study_id>09-0668 / 201105207</org_study_id>
    <nct_id>NCT00921310</nct_id>
  </id_info>
  <brief_title>Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I/II Trial of Temsirolimus and Pemetrexed in Recurrent/Refractory Non Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the
      combination of temsirolimus and pemetrexed, as well as the response rate. The starting dose
      (Dose Level 1) and schedule of pemetrexed will be 500 mg/m^2 given every 3 weeks and the
      starting dose (Dose Level 1) for temsirolimus will be 15 mg given weekly for 3 weeks, to
      complete 1 cycle. In subsequent cohorts, dose will be escalated or de-escalated. Enrollment
      to each cohort is based on toxicity experienced at that dose level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To determine the maximum tolerated dose (MTD) of temsirolimus that could be administered
           weekly in combination with pemetrexed.

        -  To determine the dose-limiting toxicity (DLT) of temsirolimus and pemetrexed as well as
           other toxicities of this combination therapy.

        -  To describe the response rate of the combination in patients with relapsed/refractory
           non-small cell lung cancer (NSCLC).

        -  To describe phospho-Akt and phospho-S6 levels in circulating mononuclear cells before
           and after treatment.

        -  To determine the response rates in patients with NSCLC when treated with temsirolimus
           and pemetrexed.

        -  To evaluate progression-free survival in patients with NSCLC when treated with
           temsirolimus and pemetrexed.

        -  To determine the one-year survival rates in patients with NSCLC when treated with
           temsirolimus and pemetrexed.

        -  To describe phospho-Akt and phospho-S6 levels in circulating mononuclear cells before
           and after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawal of funding from sponsor
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I Only: Maximum Tolerated Dose (MTD) of Pemetrexed That Could be Administered Weekly in Combination With Temsirolimus</measure>
    <time_frame>Completion of first cycle by all enrolled patients in Phase I portion of study</time_frame>
    <description>The starting dose and schedule of pemetrexed will be 500 mg/m2 given every 3 weeks and the starting dose for temsirolimus will be 15 mg given weekly for 3 weeks, to complete 1 cycle. In subsequent cohorts, dose will be escalated or de-escalated. Enrollment to each cohort is based on toxicity experienced at that dose level. The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 patients of a cohort experience dose-limiting toxicity during the first cycle. Six patients will be enrolled at the maximum tolerated dose to ensure that no more than 2 DLTs occur at the MTD. Dose escalations will proceed until the MTD has been reached.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I Only: Maximum Tolerated Dose (MTD) of Temsirolimus That Could be Administered Weekly in Combination With Pemetrexed</measure>
    <time_frame>Completion of first cycle by all enrolled patients in Phase I portion of study</time_frame>
    <description>The starting dose and schedule of pemetrexed will be 500 mg/m2 given every 3 weeks and the starting dose for temsirolimus will be 15 mg given weekly for 3 weeks, to complete 1 cycle. In subsequent cohorts, dose will be escalated or de-escalated. Enrollment to each cohort is based on toxicity experienced at that dose level. The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 patients of a cohort experience dose-limiting toxicity during the first cycle. Six patients will be enrolled at the maximum tolerated dose to ensure that no more than 2 DLTs occur at the MTD. Dose escalations will proceed until the MTD has been reached.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I Only: Number of Participants Who Experience Dose-limiting Toxicities (DLT) of Temsirolimus and Pemetrexed</measure>
    <time_frame>Completion of first cycle (approximately 21 days)</time_frame>
    <description>DLT will be defined as occurring within the first cycle of Phase I only and will be graded according to the Common Terminology Criteria for Adverse Events v 3.0 (CTCAE)
Any grade 3 or higher hematologic toxicity with the exception of anemia.
Any grade 3 or higher non-hematologic toxicity related to study therapy (except alopecia).
Grade 3 or 4 pneumonitis or esophagitis.
Treatment delay of temsirolimus for more than 14 consecutive days due to study-related toxicity.
Treatment delay of pemetrexed therapy for more than 14 consecutive days because of study-related toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I and Phase II: Overall Response Rate (Complete Response + Partial Response)</measure>
    <time_frame>2 years</time_frame>
    <description>Only those patients who have measurable disease present at baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for response.
Complete response (CR)−disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level.
Partial response (PR)−at least a 30% decrease in the sum of the longest diameter (LD) of the target lesions taking as reference the baseline sum LD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I Only: Phospho-Akt Levels in Circulating Mononuclear Cells</measure>
    <time_frame>Cycle 1 Day 1, one hour post completion of initial temsirolimus dose, and Cycle 1 Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I Only: Phospho-S6 Levels in Circulating Mononuclear Cells</measure>
    <time_frame>Cycle 1 Day 1, one hour post completion of initial temsirolimus dose, and Cycle 1 Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Only: Progression-free Survival (PFS)</measure>
    <time_frame>2 years from completion of treatment</time_frame>
    <description>PFS is defined as the duration of time from start of treatment to time of progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Only: Survival Rate</measure>
    <time_frame>1 year after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Only: Phospho-Akt Levels in Circulating Mononuclear Cells</measure>
    <time_frame>Cycle 1 Day 1, one hour post completion of initial temsirolimus dose, and Cycle 1 Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Only: Phospho-S6 Levels in Circulating Mononuclear Cells Before and After Treatment</measure>
    <time_frame>Cycle 1 Day 1, one hour post completion of initial temsirolimus dose, and Cycle 1 Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Phase I Dose Level 1 (pemetrexed + temsirolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Dose Level 1
Pemetrexed 500mg/m^2 intravenous (IV) on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Dose Level -1 (pemetrexed + temsirolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (pemetrexed + temsirolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 dose will be the maximum tolerated dose found in the Phase I portion of the study.
Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Phase I Dose Level 1 (pemetrexed + temsirolimus)</arm_group_label>
    <arm_group_label>Phase I Dose Level -1 (pemetrexed + temsirolimus)</arm_group_label>
    <arm_group_label>Phase 2 (pemetrexed + temsirolimus)</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <arm_group_label>Phase I Dose Level 1 (pemetrexed + temsirolimus)</arm_group_label>
    <arm_group_label>Phase I Dose Level -1 (pemetrexed + temsirolimus)</arm_group_label>
    <arm_group_label>Phase 2 (pemetrexed + temsirolimus)</arm_group_label>
    <other_name>Torisel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed diagnosis of NSCLC.

          -  Patients must have non-squamous histology.

          -  Patients must have measurable disease (by RECIST criteria), defined as at least one
             lesion that can be accurately measured in at least one dimension (longest diameter to
             be recorded) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan.

          -  Patients may have failed at least one prior platinum-based therapy for NSCLC or be
             candidates for first-line therapy for advanced disease deemed ineligible to receive
             platinum-based chemotherapy in the opinion of the treating physician (e.g., Eastern
             Cooperative Oncology Group (ECOG) performance status of 2, age ≥ 70, chronic medical
             condition).

          -  Patients must be at least 4 weeks out from chemotherapy, biological therapy, major
             surgery, or any investigative therapy and must have recovered from any toxicities.
             Patients must be at least 2 weeks out from prior radiation therapy and must have
             recovered from any associated toxicities (with the exception of alopecia).

          -  Patients must be at least 3 weeks out from immunosuppressive therapy (except
             corticosteroids used as antiemetics).

          -  Age ≥18 years. Because no dosing or adverse event data are currently available on the
             use of pemetrexed in combination with temsirolimus in patients &lt;18 years of age,
             children are excluded from this study.

          -  ECOG performance status 0-2.

          -  Patients must have normal organ and marrow function as defined below:

               -  hemoglobin ≥9.0 g/dL

               -  absolute neutrophil count ≥1,500/mcL

               -  platelets ≥100,000/mcL

               -  total bilirubin ≤1.5 mg/dL

               -  aspartate aminotransferase (AST)(SGOT)/ alanine aminotransferase (ALT) (SGPT)
                  ≤2.5 X institutional upper limit of normal OR ≤5 X institutional upper limit of
                  normal if enzyme abnormalities are due to liver metastases

               -  creatinine &lt; 2.0 mg/dL AND/OR

               -  creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above
                  institutional normal

               -  serum cholesterol &lt; 350 mg/dL

               -  triglycerides &lt; 300 mg/dL

          -  The effects of pemetrexed and temsirolimus on the developing human fetus at the
             recommended therapeutic dose are unknown. For this reason and because antifolate
             antineoplastic agents as well as other therapeutic agents used in this trial are known
             to be teratogenic, women of child-bearing potential and men must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             entry and for the duration of study participation. Should a woman become pregnant or
             suspect she is pregnant while participating in this study, she should inform her
             treating physician immediately.

          -  Ability of the patient (or legally authorized representative if applicable) to
             understand and the willingness to sign a written informed consent document.

          -  Both men and women and members of all races and ethnic groups are eligible for this
             trial.

        Exclusion Criteria:

          -  Patients who have had previous treatment with pemetrexed.

          -  Patients may not be receiving any other investigational agents.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, clinically significant hepatic or renal disease or neuropathy greater than
             grade 2.

          -  Symptomatic brain metastases

          -  Presence of a third-space fluid (pleural effusion, ascites etc.) that is uncontrolled
             by drainage.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to temsirolimus, its metabolites (including sirolimus), its components,
             and/or polysorbate 80, or to other agents used in the study.

          -  Known hypersensitivity to macrolide antibiotics.

          -  Patients with psychiatric illness/social situations that would limit compliance with
             study requirements and with premedications of dexamethasone, folic acid and vitamin
             B12.

          -  Patients with inability to discontinue all non-steroidal anti-inflammatory drugs
             (NSAIDS).

          -  Patients taking anticonvulsant medications (Carbamezapine, phenytoin, fosphenytoin,
             phenobarbital).

          -  Patients taking anti-arrhythmic medications (amiodarone, diltiazem and quinidine).

          -  Patients may not be taking medications known as inhibitors of CYP3A4 (carbamezapine,
             phenytoin, phenobarbital, rifampin, St. John's wort). Use of inducers of CYP3A4 is
             discouraged but not specifically prohibited. Dexamethasone as a chronic medication is
             discouraged.

          -  Pregnant women are excluded from this study because pemetrexed is an antifolate
             antineoplastic drug with the potential for teratogenic or abortifacient effects.
             Because there is an unknown but potential risk for adverse events in nursing infants
             secondary to treatment of the mother with pemetrexed, breastfeeding should be
             discontinued if the mother is treated with pemetrexed. These potential risks may also
             apply to other agents used in this study.

          -  Patients with known concomitant genetic or acquired immunosuppressive diseases are
             excluded. HIV-positive patients on combination antiretroviral therapy are ineligible
             because of the potential for pharmacokinetic interactions with pemetrexed and
             temsirolimus. In addition, these patients are at increased risk of lethal infections
             when treated with marrow-suppressive therapy. Appropriate studies will be undertaken
             in patients receiving combination antiretroviral therapy when indicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Baggstrom, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <reference>
    <citation>Russo F, Bearz A, Pampaloni G; Investigators of Italian Pemetrexed Monotherapy of NSCLC Group. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. BMC Cancer. 2008 Jul 31;8:216. doi: 10.1186/1471-2407-8-216.</citation>
    <PMID>18667090</PMID>
  </reference>
  <reference>
    <citation>Pal SK, Figlin RA, Reckamp KL. The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 2008 Nov;9(6):340-5. doi: 10.3816/CLC.2008.n.049. Review.</citation>
    <PMID>19073516</PMID>
  </reference>
  <reference>
    <citation>Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar 1;22(5):909-18.</citation>
    <PMID>14990647</PMID>
  </reference>
  <reference>
    <citation>Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res. 2008 Mar 1;14(5):1286-90. doi: 10.1158/1078-0432.CCR-07-4719. Review.</citation>
    <PMID>18316545</PMID>
  </reference>
  <reference>
    <citation>Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006 Nov 6;95(9):1148-54. Epub 2006 Oct 10.</citation>
    <PMID>17031397</PMID>
  </reference>
  <reference>
    <citation>Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grünwald V, Weiss G, Hidalgo M. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clin Cancer Res. 2003 Aug 1;9(8):2887-92.</citation>
    <PMID>12912932</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <results_first_submitted>August 10, 2016</results_first_submitted>
  <results_first_submitted_qc>October 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2016</results_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Temsirolimus and pemetrexed for recurrent or refractory NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened to participant enrollment on 09/28/2009 and closed to participant enrollment on 12/20/2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I Dose Level 1 (Pemetrexed &amp; Temsirolimus)</title>
          <description>Pemetrexed 500mg/m^2 intravenous (IV) on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
        </group>
        <group group_id="P2">
          <title>Phase I Dose Level -1 (Pemetrexed &amp; Temsirolimus)</title>
          <description>Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
        </group>
        <group group_id="P3">
          <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
          <description>Phase 2 dose will be the maximum tolerated dose found in the Phase I portion of the study.
Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I (Premetrexed &amp; Temsirolimus)</title>
          <description>Participants enrolled in the Phase I portion Dose Level 1 received:
Pemetrexed 500mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle
Participants enrolled in the Phase I portion Dose Level -1 received:
Pemetrexed 375mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
        </group>
        <group group_id="B2">
          <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
          <description>-Participants enrolled in the Phase 2 portion received:
Pemetrexed (375 mg/m2^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" lower_limit="49" upper_limit="76"/>
                    <measurement group_id="B2" value="67.5" lower_limit="62" upper_limit="70"/>
                    <measurement group_id="B3" value="62.5" lower_limit="49" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase I Only: Maximum Tolerated Dose (MTD) of Pemetrexed That Could be Administered Weekly in Combination With Temsirolimus</title>
        <description>The starting dose and schedule of pemetrexed will be 500 mg/m2 given every 3 weeks and the starting dose for temsirolimus will be 15 mg given weekly for 3 weeks, to complete 1 cycle. In subsequent cohorts, dose will be escalated or de-escalated. Enrollment to each cohort is based on toxicity experienced at that dose level. The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 patients of a cohort experience dose-limiting toxicity during the first cycle. Six patients will be enrolled at the maximum tolerated dose to ensure that no more than 2 DLTs occur at the MTD. Dose escalations will proceed until the MTD has been reached.</description>
        <time_frame>Completion of first cycle by all enrolled patients in Phase I portion of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I (Premetrexed &amp; Temsirolimus)</title>
            <description>Participants enrolled in the Phase I portion Dose Level 1 received:
Pemetrexed 500mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle
Participants enrolled in the Phase I portion Dose Level -1 received:
Pemetrexed 375mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
            <description>-Participants enrolled in the Phase 2 portion received:
Pemetrexed (375 mg/m2^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I Only: Maximum Tolerated Dose (MTD) of Pemetrexed That Could be Administered Weekly in Combination With Temsirolimus</title>
          <description>The starting dose and schedule of pemetrexed will be 500 mg/m2 given every 3 weeks and the starting dose for temsirolimus will be 15 mg given weekly for 3 weeks, to complete 1 cycle. In subsequent cohorts, dose will be escalated or de-escalated. Enrollment to each cohort is based on toxicity experienced at that dose level. The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 patients of a cohort experience dose-limiting toxicity during the first cycle. Six patients will be enrolled at the maximum tolerated dose to ensure that no more than 2 DLTs occur at the MTD. Dose escalations will proceed until the MTD has been reached.</description>
          <units>mg/m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase I Only: Maximum Tolerated Dose (MTD) of Temsirolimus That Could be Administered Weekly in Combination With Pemetrexed</title>
        <description>The starting dose and schedule of pemetrexed will be 500 mg/m2 given every 3 weeks and the starting dose for temsirolimus will be 15 mg given weekly for 3 weeks, to complete 1 cycle. In subsequent cohorts, dose will be escalated or de-escalated. Enrollment to each cohort is based on toxicity experienced at that dose level. The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 patients of a cohort experience dose-limiting toxicity during the first cycle. Six patients will be enrolled at the maximum tolerated dose to ensure that no more than 2 DLTs occur at the MTD. Dose escalations will proceed until the MTD has been reached.</description>
        <time_frame>Completion of first cycle by all enrolled patients in Phase I portion of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I (Premetrexed &amp; Temsirolimus)</title>
            <description>Participants enrolled in the Phase I portion Dose Level 1 received:
Pemetrexed 500mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle
Participants enrolled in the Phase I portion Dose Level -1 received:
Pemetrexed 375mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
            <description>-Participants enrolled in the Phase 2 portion received:
Pemetrexed (375 mg/m2^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I Only: Maximum Tolerated Dose (MTD) of Temsirolimus That Could be Administered Weekly in Combination With Pemetrexed</title>
          <description>The starting dose and schedule of pemetrexed will be 500 mg/m2 given every 3 weeks and the starting dose for temsirolimus will be 15 mg given weekly for 3 weeks, to complete 1 cycle. In subsequent cohorts, dose will be escalated or de-escalated. Enrollment to each cohort is based on toxicity experienced at that dose level. The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 patients of a cohort experience dose-limiting toxicity during the first cycle. Six patients will be enrolled at the maximum tolerated dose to ensure that no more than 2 DLTs occur at the MTD. Dose escalations will proceed until the MTD has been reached.</description>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase I Only: Number of Participants Who Experience Dose-limiting Toxicities (DLT) of Temsirolimus and Pemetrexed</title>
        <description>DLT will be defined as occurring within the first cycle of Phase I only and will be graded according to the Common Terminology Criteria for Adverse Events v 3.0 (CTCAE)
Any grade 3 or higher hematologic toxicity with the exception of anemia.
Any grade 3 or higher non-hematologic toxicity related to study therapy (except alopecia).
Grade 3 or 4 pneumonitis or esophagitis.
Treatment delay of temsirolimus for more than 14 consecutive days due to study-related toxicity.
Treatment delay of pemetrexed therapy for more than 14 consecutive days because of study-related toxicity.</description>
        <time_frame>Completion of first cycle (approximately 21 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I Dose Level 1 (Premetrexed &amp; Temsirolimus)</title>
            <description>Pemetrexed 500mg/m^2 intravenous (IV) on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Level -1 (Pemetrexed &amp; Temsirolimus)</title>
            <description>Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
            <description>Phase 2 dose will be the maximum tolerated dose found in the Phase I portion of the study.
Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I Only: Number of Participants Who Experience Dose-limiting Toxicities (DLT) of Temsirolimus and Pemetrexed</title>
          <description>DLT will be defined as occurring within the first cycle of Phase I only and will be graded according to the Common Terminology Criteria for Adverse Events v 3.0 (CTCAE)
Any grade 3 or higher hematologic toxicity with the exception of anemia.
Any grade 3 or higher non-hematologic toxicity related to study therapy (except alopecia).
Grade 3 or 4 pneumonitis or esophagitis.
Treatment delay of temsirolimus for more than 14 consecutive days due to study-related toxicity.
Treatment delay of pemetrexed therapy for more than 14 consecutive days because of study-related toxicity.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase I and Phase II: Overall Response Rate (Complete Response + Partial Response)</title>
        <description>Only those patients who have measurable disease present at baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for response.
Complete response (CR)−disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level.
Partial response (PR)−at least a 30% decrease in the sum of the longest diameter (LD) of the target lesions taking as reference the baseline sum LD</description>
        <time_frame>2 years</time_frame>
        <population>(4) patients in Phase 1 were not evaluable for response as they were removed from study prior to week 6 scans. One patient in Phase 2 was not evaluable due to expiring prior to week 6 scans.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I (Premetrexed &amp; Temsirolimus)</title>
            <description>Dose Level 1
Pemetrexed 500mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle
Dose Level -1
Pemetrexed 375mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
            <description>Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I and Phase II: Overall Response Rate (Complete Response + Partial Response)</title>
          <description>Only those patients who have measurable disease present at baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for response.
Complete response (CR)−disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level.
Partial response (PR)−at least a 30% decrease in the sum of the longest diameter (LD) of the target lesions taking as reference the baseline sum LD</description>
          <population>(4) patients in Phase 1 were not evaluable for response as they were removed from study prior to week 6 scans. One patient in Phase 2 was not evaluable due to expiring prior to week 6 scans.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase I Only: Phospho-Akt Levels in Circulating Mononuclear Cells</title>
        <time_frame>Cycle 1 Day 1, one hour post completion of initial temsirolimus dose, and Cycle 1 Day 8</time_frame>
        <population>Due to early termination of the study by withdrawal of funding by sponsor (Pfizer merged with Wyeth), the peripheral blood samples that were collected for this outcome measure were not analyzed prior to losing funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I (Premetrexed &amp; Temsirolimus)</title>
            <description>Dose Level 1
Pemetrexed 500mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle
Dose Level -1
Pemetrexed 375mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
            <description>Pemetrexed (375 mg/m2^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I Only: Phospho-Akt Levels in Circulating Mononuclear Cells</title>
          <population>Due to early termination of the study by withdrawal of funding by sponsor (Pfizer merged with Wyeth), the peripheral blood samples that were collected for this outcome measure were not analyzed prior to losing funding.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase I Only: Phospho-S6 Levels in Circulating Mononuclear Cells</title>
        <time_frame>Cycle 1 Day 1, one hour post completion of initial temsirolimus dose, and Cycle 1 Day 8</time_frame>
        <population>Due to early termination of the study by withdrawal of funding by sponsor (Pfizer merged with Wyeth), the peripheral blood samples that were collected for this outcome measure were not analyzed prior to losing funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I (Premetrexed &amp; Temsirolimus)</title>
            <description>Dose Level 1
Pemetrexed 500mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle
Dose Level -1
Pemetrexed 375mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
            <description>Pemetrexed (375 mg/m2^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I Only: Phospho-S6 Levels in Circulating Mononuclear Cells</title>
          <population>Due to early termination of the study by withdrawal of funding by sponsor (Pfizer merged with Wyeth), the peripheral blood samples that were collected for this outcome measure were not analyzed prior to losing funding.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Only: Progression-free Survival (PFS)</title>
        <description>PFS is defined as the duration of time from start of treatment to time of progression.</description>
        <time_frame>2 years from completion of treatment</time_frame>
        <population>There were only (2) patients evaluable for PFS.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I (Premetrexed &amp; Temsirolimus)</title>
            <description>Dose Level 1
Pemetrexed 500mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle
Dose Level -1
Pemetrexed 375mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
            <description>Pemetrexed (375 mg/m2^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Only: Progression-free Survival (PFS)</title>
          <description>PFS is defined as the duration of time from start of treatment to time of progression.</description>
          <population>There were only (2) patients evaluable for PFS.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patient A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Only: Survival Rate</title>
        <time_frame>1 year after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I (Premetrexed &amp; Temsirolimus)</title>
            <description>Dose Level 1
Pemetrexed 500mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle
Dose Level -1
Pemetrexed 375mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
            <description>Pemetrexed (375 mg/m2^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Only: Survival Rate</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Only: Phospho-Akt Levels in Circulating Mononuclear Cells</title>
        <time_frame>Cycle 1 Day 1, one hour post completion of initial temsirolimus dose, and Cycle 1 Day 8</time_frame>
        <population>Due to early termination of the study by withdrawal of funding by sponsor (Pfizer merged with Wyeth), the peripheral blood samples that were collected for this outcome measure were not analyzed prior to losing funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I (Premetrexed &amp; Temsirolimus)</title>
            <description>Dose Level 1
Pemetrexed 500mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle
Dose Level -1
Pemetrexed 375mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
            <description>Pemetrexed (375 mg/m2^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Only: Phospho-Akt Levels in Circulating Mononuclear Cells</title>
          <population>Due to early termination of the study by withdrawal of funding by sponsor (Pfizer merged with Wyeth), the peripheral blood samples that were collected for this outcome measure were not analyzed prior to losing funding.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Only: Phospho-S6 Levels in Circulating Mononuclear Cells Before and After Treatment</title>
        <time_frame>Cycle 1 Day 1, one hour post completion of initial temsirolimus dose, and Cycle 1 Day 8</time_frame>
        <population>Due to early termination of the study by withdrawal of funding by sponsor (Pfizer merged with Wyeth), the peripheral blood samples that were collected for this outcome measure were not analyzed prior to losing funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I (Premetrexed &amp; Temsirolimus)</title>
            <description>Dose Level 1
Pemetrexed 500mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle
Dose Level -1
Pemetrexed 375mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
            <description>Pemetrexed (375 mg/m2^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Only: Phospho-S6 Levels in Circulating Mononuclear Cells Before and After Treatment</title>
          <population>Due to early termination of the study by withdrawal of funding by sponsor (Pfizer merged with Wyeth), the peripheral blood samples that were collected for this outcome measure were not analyzed prior to losing funding.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phase I (Premetrexed &amp; Temsirolimus)</title>
          <description>Dose Level 1
Pemetrexed 500mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle
Dose Level -1
Pemetrexed 375mg/m^2 IV on Day 1 of each 21 day cycle
Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle</description>
        </group>
        <group group_id="E2">
          <title>Phase 2 (Pemetrexed &amp; Temsirolimus)</title>
          <description>Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle
Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression - death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophils (ANC)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Leukocytes (WBC)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aspiration pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Watery eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Viral flare (herpes)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Chloesterol - high</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hand pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Leukocytes (WBC)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophils (ANC)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Throat pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Triglycerides - high</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin - low</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Calcium - low</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Glucose - high</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Magnesium - low</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Phosphorus - low</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Potassium - high</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sodium - low</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mood alteration - anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mood alteration - depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maria Baggstrom, M.D.</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-5737</phone>
      <email>mbaggstr@dom.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

